Sarepta Therapeutics Inc. (NASDAQ:SRPT)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for SRPT
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- woodman: $SRPT - interesting. https://www.biopharmadive.com/news/sarepta-elevidys-sales-duchenne-gene-therapy-second-quarter-2024/723677/
- woodman: $SRPT is at an interesting spot with this pullback to the 50d. It reports today amc. I think it could beat and raise guidance. But not sure I want to gamble on it.....
- woodman: $PFE $SRPT - Pfizer's DMD Phase 3 fail leaves SRPT (PDUFA 6/21) as the only game in town. https://www.fiercebiotech.com/biotech/pfizers-phase-3-gene-therapy-trial-fails-improve-function-boys-duchenne-muscular-dystrophy
- joelsg1: @woodman $PFE $SRPT Never liked $SRPT on MD since it got the nod over $BMRN, word then was it was close but FDA approved $SRPT to give some hope to families affected by MD, not that their drug worked that well. Tough nut to crack.
- woodman: @joelsg1 $PFE $SRPT $BMRN - I have no skin in the DMD TA. I think it will be approved, but it may have a strict/limiting label. The testimony of parents whose kids have improved quite a bit is compelling.
- Mikev200: $SRPT Sarepta Therapeutics (SRPT) reported earnings of $0.73 per share on revenue of $413.46 million for the first quarter ended March 2024. The consensus estimate was a loss of $0.07 per share on revenue of $372.80 million. The Earnings Whisper number was $0.03 per share. The company beat expectations by 2,333.33% while revenue grew 63.10% on a year-over-year basis. I guess not good enough :))
- camaro69: $SRPT up nice pre mkt on news
- camaro69: $SRPT holding it's gap up for the moment
- camaro69: $SRPT held its gap up for now
- GOOSE: $SRPT On P&F chart, AT A DOUBLE TOP, @84.0, 85.0 BREAKS IT GIVING A BUY SIGNAL, GOING TO BUY A WEE BIT JUST TO KEEP AN EYE ON IT.
- GOOSE: $SRPT BTO STOCK @ 83.98
- shoredriver: $SRPT.....glad I did not sell the 11/3 80's...
- GOOSE: TRADES: $UPST STO 11/10/23 28.50 CALLS @2.12, and 29.50 CALLS @1.75 $SRPT BTO STOCK @ 79.23 and 79.87 $SRPT STO 11/10/23 80.9 CALLS @1.85
- shoredriver: $SRPT....nice....started nibbling around 62....looking to swing as sell some of this Fridays calls....maybe 80's....
- shoredriver: $SRPT new HOD....yaaassss.....
- woodman: @shoredriver $SRPT - Nice job!
- GOOSE: I'm getting ready to sell $SRPT, earnings after bell. YOU????
- GOOSE: Out of $SRPT. TOMORROW IS ANOTHER DAY TO HAVE SOME FUN. ;>)
- Motorman: @GOOSE $SRPT Nice trade!
- wijimmy: $SRPT ..... OUCH !!!!!! DOWN -46% and reports TOMORROW !!!! down due to... Sarepta Therapeutics' Shares Plummet to 5-Year Low as Duchenne Muscular Dystrophy Results Miss Trial Goal.... ... ... Nice quick BOUNCE....... Morgan Stanley Adjusts Price Target on Sarepta Therapeutics to $146 From $183, Maintains Overweight Rating 10/31/2023 09:03AM • MT Newswires ... Nice quick BOUNCE.....
- scottrades: @wijimmy $SRPT Wow....
- GOOSE: A GAMBLE, not a trade: $SRPT BTO STOCK @61.25 One round lot.
- joelsg1: @wijimmy $SRPT When their DMD drug was approved initially by FDA over a competing drug from $BMRN, as I recall they overruled staff as it wasn't clear either drug really worked but there was great political pressure from parents of children with this terrible condition for some hopeful cure.. Coming home to roost now.
- GOOSE: A TRADE: $SRPT STO 11/10/23 65.0 CALL @3.75 Covered
- GOOSE: TRADE: $SRPT added 2 more round lots @63.67 & 64.85 Reporting tomorrow in the PM.
- GOOSE: A TRADE: $SRPT BTC 11/10/23 65.0 CALL @5.00 STO @3.75
- shoredriver: $SRPT....down 14% on FDA delay ..watching...
- Auto: $CVX $SRPT added long daily
- Nepenthe: @Auto $CVX $SRPT Do you know what's going on with $AQUA? Disappeared from my trading screen. Cheers.
- Auto: @Nepenthe $CVX $SRPT $AQUA $AQUA completes Acquisition with Evoqua the ticker XYL
- shoredriver: $SRPT....not bouncy....at least not yet...watching
- camaro69: $SRPT HOD
- Bridgemate: $SRPT ?
- Henry: @Bridgemate $SRPT FDA meeting today
- Bridgemate: @Henry $SRPT thank you
- scottrades: Some Earnings after the close today: $AMD $F $SBUX $ET $SMCI $LTHM $CZR $PAYC $LUMN $MTCH $SPG $CLX $CHK $OKE $YUMC $WU $PRTS $DVAX $TRVG $SAR $PRU $ARWR $BAND $NRDS $SRPT $CWH $OHI $PACB $DENN $BGFV $MUSA $EQX $HLF $INSP $SPT $ANDE $APLE $WELL $AFG $CRK $AKR $EXPI $CLW $HRZN $MTW $FRSH $LSI $EXR $ATGE $UNM
- shoredriver: $SRPT...ouch.....
- shoredriver: @shoredriver $SRPT ....NP.....
- woodman: @shoredriver $SRPT - Adam Feuerstein/STAT hit piece. Bouncing nicely afterward. Feuerstein has been attacking SRPT forever. He's a nutty often irrational guy who, by the way, has a political science degree. Nothing in the physical sciences or medicine. But somehow he's managed to get a reputation as a biotech know-it-all. Watching him over the years, he puts many companies on his sh*t list and they never come off. He never admits he's wrong about anything. And he has been wrong many times.
- woodman: $SRPT - good action, holding its move up through descending resistance a couple days ago. PDUFA 5/29; AdCom likely late this month or early next. I'm still in this with a position I started on collapse day 3/17. I'm thinking it goes higher into the AdCom, but the AdCom itself will move the stock one way or the other, for sure.
- sierramp: @woodman $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech Thank you for this. Can't buy them using my usual process for evaluation but very, very interesting so attempting to come up with another way to evaluate. If you have time, would you share how they pass your test?
- woodman: @sierramp $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech - Catalysts (trial data due; FDA decisions due, etc.), important therapeutic areas and potential moats, interesting combos with established companies and institutions, strong interest by people I respect. Not all of these necessarily apply to each and every one, but some of these elements apply to each. Not an exhaustive list, but what instantly came to mind. Fwiw, I provided a small bit of color on most of these in a prior recent post here that you can search for. The chart is a factor, but to a more limited extent - less so than my ordinary trading MO.
- pperlroth: @woodman $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech These are great! Thank you for sharing as I often look to this industry as the payouts can be massive given potential takeovers AND potential FDA approvals for new drugs/therapies.
- woodman: Updated list of #Biotech that I'm currently in ($$ amounts vary; not in any particular order): $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR (bought today).
- scottrades: My notes: $SPY $QQQ Santa Rally? More like Santa Short Covering $GDX Going sideways $SLV Holding the 8EMA $XLE Choppy $XBI Tight $VRNA Consider more profits if you’re long $CPRX Don’t lose sight of this $VRTX Would like to see it tighten up $SRPT Working $CAH Holding the 8EMA $SHLS Still holding the 50 Day $ARRY Nice volume into the close $CROX Holding the 8EMA $G Tight weekly $Four High Handle $ELF Holding the 21 EMA $WPM Sold and bought some back $GOLD closed above the 8EMA
- woodman: Current #biotech and Big #Pharma that I'm in: $ARDX (gift drop 2 days ago; catalyst with news likely in January - see my prior posts) $CPRX (keeps going) $ORMP (strong today; catalyst into January for P3 results for oral insulin; also, CEO just talke ...
- camaro69: @scottrades $SPY $QQQ $DIA $UUP $SMH $XBI $TAN $XLV $XLE $OIH $BITO $AAPL $META $TSLA $MSFT $ENPH $ARRY $SHLS $FSLR $NVDA $ON $PENN $CPRX $ITCI $SRPT $PRVB $UNH $Great Video Scott. Thanks for going over the moving averages in depth.
- scottrades: My notes: $SPY At the 200 Day $QQQ At the 100 EMA $DIA Downside Reversal $UUP Under the 200 Day $SMH Above the 200 Day $XBI MAs are stacked $TAN Holding the 8EMA $XLV Working $XLE Traded tight all day, hard to find good setups $OIH Above the 50 Day, hard to find good setups $BITO Stopped at the 50 Day $AAPL Downside reversal $META Held the gap $TSLA at the 200 Week MA. $MSFT Rejected at the 200 Day $ENPH Still in an uptrend $ARRY Bought this today $SHLS Above all the MAs $FSLR At the 21 EMA $NVDA Above the 200 Day $ON At the 8EMA $PENN Out of the wedge $CPRX This is on the ATL $ITCI Clear resistance. $SRPT Watch 124 $PRVB from @lauralynnee in the forum. $UNH Watch 555
- lauralynnee: @scottrades $SPY $QQQ $DIA $UUP $SMH $XBI $TAN $XLV $XLE $OIH $BITO $AAPL $META $TSLA $MSFT $ENPH $ARRY $SHLS $FSLR $NVDA $ON $PENN $CPRX $ITCI $SRPT $PRVB $UNH Thanks @Scottrades for covering $PRVB tonight, and you got my name right!
- Angdionk: $SRPT bouncing off 21DMA
- scottrades: $SRPT Higher Lows and higher Highs. A bit extended above the 8EMA. Watch for a PB to the MAs.
- woodman: @scottrades $SRPT - This makes me sad. I had it and got shaken out, then let it get away. Congrats to those who didn't get faked out.
- woodman: $SRPT left me in the dust. I got out in early Nov., didn't pay attention afterward, and it has bounced back, now breaking out of its sideways range.
- jpoko13: $SRPT Big move into the blue
- woodman: $SRPT - Looking for something to kick that won't hurt my foot too much! This shook me out. It was a fake-out! I held for a while but sold when it collapsed under the 50d and then the last of it when it couldn't hold the channel. But it reversed back up, all the way to top of the channel, without me. It even broke through top of the channel this morning, though now falling back in.
- fiebs: $SRPT moving this morning
- woodman: $SRPT has moved back up to the 50d after a not so nice fall through it 2 weeks ago. If it rolls over here, it could be a decent short.
- woodman: $SRPT -Collapsing out of range, look out below. Stopped out of the shares I tried to pick off the bottom of the range. Glad I sold most before earnings.
- joelsg1: @woodman $SRPT Never liked this co. or their MD drug, ever since they beat $BMRN for govt. approval on dubious data. Almost any new drug would do better. Good riddance.
- woodman: @joelsg1 $SRPT $BMRN - I thought if it could breakout to the upside, it could fill the rest of the gap up to 161 possible, but I didn't trust it which is why I sold most before earnings. Managed a profit but was hoping for much more. Oh well.
- joelsg1: @woodman $SRPT $BMRN Book it Dano! (Old Hawaii 5 0 reference)
- woodman: @joelsg1 $SRPT $BMRN - I'm old enough to recall the reference. (Unfortunately.)
- woodman: $SRPT - sold 2/3 of mine yesterday before its amc report yesterday. It has dropped to around the bottom of its nearly 3-month range. This is also a drop below the 50d which of course isn't what we want to see. But because it is holding the bottom of this range, I bought some back (~106). It has to hold 103 (bottom of the range) for me to stay aboard.
- woodman: $SRPT major squeeze in this biotech. Beware: earnings after the bell today, and it could move a lot (up or down) depending on the corporate updates.
-
DAN: ...
$SRPT -- Still squeezing. Earnings on Wednesday. Alert $115
$SRTS -- Tightening up here. Earnings on Thursday. Alert $14
$GMAB -- Holding up above $30. Alert $39.20
- roddog101: @DAN $ROST $OLLI $SPY $T2108 $T2107 $DIA $IYT $MDY $IWM $QQQ $NDX $NVDA $AAPL $META $GOOGL $AMZN $MSFT $TBT $TWNK $LLY $SGML $HSY $SARK $VRTX $CECE $TA $SRPT $SRTS $GMAB Dan check out $INMD
-
DAN: ...
$SRPT -- Alert $117
$MCK -- Still going on Phase 1. Too late to buy here!
$SRTS -- Alert $14.20
Other stocks I am watching.
Oil & Gas Refining & Marketing / Basic Materials
$DINO -- Drew horizontal line on 10/14. Now starting to break ... -
DAN: ...
$SRPT -- “too wide” from yesterday.
$TBT - Basis: 30.40. Stop: 31.80 Up 18% easy trade.
$LLY - Basis: 333.05 Stop: 312.00
$CEIX - Stopped at 65.90
$SGML - Basis: 31.30 Stop: 26.40
$TWNK -Basis: 24.04 Stop 22.80. Just grinding aroun ... - Bert953: $SRPT trend kicker in volatility squeeze. reports 11/1 but Im cautious here. 3rd 15 min candle on indexes is tiny, so it looks like buying has dried up. A dangerous market cause those paper cuts add up.
- issues: IBD not working due to maintenance but here are the IBD 50 for this week: $CCRN $MTDR $VRTX $WWE $PXD $SRPT $CIVI $EOG $COP $TALO $NOG $HRMY $FANG $SM $PERI $CVI $DVN $DECK $AMN $MOH $AHCO $DAR $MRK $HAE $EBC $HUM $MRO $LW $OXY $AMR $TTC $WAFD $NBIX $HES $APA $VNOM $PDCE $ERF $HCC $SLVM $PCAR $ONB $CORT $GMAB $CVBF $TNK $PNFP $CADE $GBCI $UCBI
- woodman: $SRPT - 2.2 months of consolidation into rising 50d. BBs getting pretty narrow.
- woodman: @woodman $SRPT - $50 of gap left to fill if the gods so decide.
- scottrades: $SRPT trying to move here
- scottrades: $SRPT Basing
- woodman: $SRPT has drifted sideways into its rising 50d. Still consolidating (now for nearly 2 months) within a lower portion of the huge gap created by the 1/8/2021 dive. Much more gap still to fill ... potentially. I'm still holding this.
- scottrades: My notes: $SPY/$QQQ the bounce is on $UUP Around the 21 EMA $XLE Back above the 650 Day $TAN Running into the MAs $GDX Great volume $TSLA Watch for underperformance $TWTR Congrats Longs $FSLR Sold Half $ENPH Downside reversal $MAXN Closed near the lows $SHLA at the 50 Day $DV Working, tight action $WWE Chart of the Day $DG Basing $LTHM Watch 32.60 $REGN Extended but working $VRTX Working $SRPT Watch 113.70 $PRVA Support at the 100 EMA $ALB Back above the MAs
- woodman: Still not doing much. Raised my stop on $TBT which I purchased a couple times last week (stop now under the low of the day today), added a wee bit of $SARK on move back up through VWAP earlier this morning. Still holding $SRPT (not a "short term" trade; been adding at low spots of the nearly two-month range/consolidation b/c it's one I want hold unless it fails to hold ~103 level), $VRTX (similar to my outlook on SRPT) and $ELF. That's it at the moment. Looking at various things but not at all eager to dive in on the long side.
- woodman: $SRPT - FWIW - bouncing at bottom of recent 1.5 month range which coincides with rising 50d and what was prior resistance (new support) during the very long basing period from Jan 2021 to beginning of last month.
- woodman: @DAN - A couple biotechs: $SRPT $VRTX
- woodman: $SRPT making a new daily high here. Has a little more work to do to get back above the 8dEMA, but on the whole -- and despite a daily dip yesterday that had it move below the prior low of this consolidation range (but with a close back within range) -- I still view this as consolidation moving sideways into the rising 50d. All told, I think this is healthy, and *potential* for further gap-fill from Jan 2021 fall still intact. (Note, I haven't seen my crystal ball in months.)
- steve71: @woodman $SRPT $MYOV Consult ouija board re crystal ball location. Sarepta looks like a good bet. Myovant is my largest biotech position based on two unique approved drugs for 3 common prostate and gyn indications. Connected with both PFE and Sumitomo, either of which could take out MYOV.
- woodman: @steve71 $SRPT $MYOV - I loaned my ouija board to my tarot card reader. But I did find my chicken bone necklace, so all is good. Thanks for the MYOV tip. I'll check it out. Any thoughts on a buyout price for MYOV?
- steve71: @woodman $SRPT $MYOV Guessing a price is complicated. Sumitomo owns 52% of Myovant and has a history of completing partial purchases. PFE owns little or nothing but is 50% partnered on the two approved drugs. Both drugs are growing nicely as they are unique centrally acting agents.
- woodman: @steve71 $SRPT $MYOV Thanks.
- woodman: $SRPT - trying to bounce back from yesterday's big drop, which I think in good part had more to do with its announcement that it seeks to raise $900 million in anticipation of accelerated approval than the overall awful Market drop yesterday. There remains a large gap to fill (up to 161 from a huge drop in Jan 2021 that halved the stock) if it's so inclined, and it is currently holding the 200w moving average. That said, it has dropped below the 21dEMA support level, and revisiting the lower $98-$100 level is still a possibility. I do still hold this stock. https://endpts.com/eyeing-accelerated-approval-for-duchenne-gene-therapy-sarepta-hopes-to-bring-in-1b-in-bid-for-profitability/
- issues: @woodman $SRPT I added to SRPT!
- woodman: $SRPT @motorman - some news if you haven't already seen it. Just an FYI. https://endpts.com/eyeing-accelerated-approval-for-duchenne-gene-therapy-sarepta-hopes-to-bring-in-1b-in-bid-for-profitability/
- Motorman: @Woodman $SRPT had a little squeeze on daily, seems like a phase 2 retest. No newsier drop today. Rebounded a few points.
- woodman: @Motorman $SRPT agree re the phase 2 retest. I'm still long.
- Motorman: @woodman $SRPT Did not see the drop today, and with this week full of economic data, might get a better add point. Holding small position.
- woodman: @Motorman $SRPT - no adding for me today.
-
DAN: ...
$SRPT -- it is so high above the 50-day MA. Very steep run. Icarus.
$OHI -- 8.3% yield. Long term health care facilities
$CLH -- Strong growth profile over last 8 years. .02 to [3.64 → 6.81 (87% jump)] 6.81 (2022). 6.84 2023 - woodman: $SRPT continues to gap-fill - 161 is where that gap ends.
- woodman: $SRPT - I remain long this one from lower. It's consolidating now within a gap that goes all the way up to 161, created by a huge fall that halved the stock price in January of 2021. After that, it based throughout 2021 and 2022, but the course has been back up since June. This consolidation is a weekly flag with 200 week (and 21dEMA) support.
- woodman: $STEM - a little consolidation and moving off 20d support. $SRPT - broke out a bit from sideways consolidation yesterday; today it's holding that level nicely, developing beginning of a flag.
- woodman: $SRPT - [My post on this a little while ago was buried elsewhere.] This broke out a bit from sideways consolidation yesterday; today it's holding that level nicely, developing beginning of a flag.
- woodman: $SRPT - Been in this since 8/4 and holding. Added more this morning. It's now making a new recent high as it continues to fill the huge gap from January 2021. That gap goes to 161.
- woodman: @Motorman $BCRX - not bad, but chartwise (similar move) I like $SRPT better with big gap still to fill.
- debeers: IF/THEN-If we are going into recession, then healthcare will be a natural safety trade. Biotech is the mover and so $SRPT(from @Woodman) and $KYMR mine. Like both. Have both. LONG
- woodman: $SRPT - No let up today. Up 80% from June bottom, but also second day of filling the massive gap from Jan 2021. Extended on the daily, obviously, but lots of room to get back up to Dec. 2020 ath. (I am long this one.)
| Stock Price | $114.03 |
| Change | 3.19% |
| Volume | 426,997 |
Sarepta Therapeutics Inc discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen.
Request Video of SRPTAlready a member? Sign in here.
Past Month
Leading Peers
-
$15.26 195.71%
-
$15.60 132.66%
-
$141.38 111.57%
Past Month
Lagging Peers
-
$7.60 -85.89%
-
$8.92 -56.98%
-
$6.54 -56.79%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!